Nuvei anticipates its quarterly revenue growth rates and Adjusted EBITDA margins to increase throughout the year, aiming to align with the company's medium-term revenue growth target of 15 – 20%. The firm's underlying Adjusted EBITDA margin expectation is between 36 – 37% for Q1 2024.
I've been watching them for a bit, and I felt like they were a bit oversold on news today. Obviously they bounced nicely and were on the way up slowly before the rest of the market bounced.$Cerence (CRNC.US)$$Everbridge (EVBG.US)$$NUVEI (Delisted) (NVEI.US)$ Price to 2023 earnings is around 20 at this level and theyve got a pretty solid market presence. Question for them is can they expand outside the auto industry?
NUVEI (Delisted) Stock Forum
• $Fortinet (FTNT.US)$ : BMO Capital Upgrades to Outperform from Market Perform - PT $350 (from $325)
• $Microchip Technology (MCHP.US)$ : Stifel Upgrades to Buy from Hold - PT $75 (from $70)
• $Ovintiv (OVV.US)$ : JPMorgan Upgrades to Overweight from Neutral - PT $64 (from $56)
• $Riot Platforms (RIOT.US)$ : Compass Point Upgrades to Buy from Neutral - PT $14 (from $30)
• $Snowflake (SNOW.US)$ : Jefferies Upgrades to Buy f...
• $American Airlines (AAL.US)$ : JP Morgan Upgrades to Neutral From Underweight - PT $26 (from $18)
• $The AZEK (AZEK.US)$ : Citigroup Upgrades to Buy from Neutral - PT $30 (from $36)
• $BXP Inc (BXP.US)$ : Mizuho Upgrades to Buy from Neutral - PT $135 (from $120)
• $Dow Inc (DOW.US)$ : Citigroup Upgrades To Buy From Neutral - PT $82 (from $70)
• $The Kroger (KR.US)$ : Exane Upgrades to Neutral from Underperform - PT $60
• $Milestone Pharmaceuticals (MIST.US)$ : Piper S...
Price to 2023 earnings is around 20 at this level and theyve got a pretty solid market presence. Question for them is can they expand outside the auto industry?
No comment yet